Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Haematologica. 2020 Aug;105(8):e404-e407. doi: 10.3324/haematol.2019.236810. Epub 2019 Nov 21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cladribine* / therapeutic use
  • Cytarabine / therapeutic use
  • Female
  • Filgrastim / therapeutic use
  • Humans
  • Hydrazines
  • Leukemia, Myeloid, Acute* / drug therapy
  • Male
  • Mice, Inbred C57BL
  • Middle Aged
  • Remission Induction
  • Treatment Outcome
  • Triazoles
  • Young Adult

Substances

  • Hydrazines
  • Triazoles
  • Cytarabine
  • selinexor
  • Cladribine
  • Filgrastim